In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme to buy Novazyme for $137.5mm in stock, plus earn-out

Executive Summary

Genzyme General is buying Novazyme, a company developing therapeutics to treat lysomal storage disorders, plus related technologies. It will issue Novazyme shareholders $137.5mm in stock, plus an earn-out of up to $87.5mm in stock if two products that use its technology make it to market.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Stock

Related Companies